Ring Nitrogen Is Shared By Two Of The Cyclos Patents (Class 514/294)
-
Publication number: 20100159034Abstract: The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 15, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100159033Abstract: The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 25, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz
-
Patent number: 7736636Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of Nicotine, nicotinic acid analogs thereof, their combination with or without other pro-angiogenesis factors, vasodilator, or other therapeutic modalities to promote angiogenesis in the subject. This is composition and combination thereof is applicable to improving wound healing, erectile dysfunction, improving collateral or blood supply in patients with myocardial infarction, stroke, peripheral artery diseases, and other vascular disorders as disclosed.Type: GrantFiled: February 11, 2004Date of Patent: June 15, 2010Inventors: Shaker Mousa, Sarah Mousa
-
Publication number: 20100137353Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials.Type: ApplicationFiled: April 17, 2008Publication date: June 3, 2010Applicant: GLAXO GROUP LIMITEDInventor: Neil David Pearson
-
Publication number: 20100130528Abstract: The present invention relates to new adamantane modulators of NMDA receptors and/or 5HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100130480Abstract: The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 18, 2009Publication date: May 27, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz
-
Patent number: 7713969Abstract: The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.Type: GrantFiled: February 9, 2006Date of Patent: May 11, 2010Assignee: ArQule, Inc.Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi M. Moussa, Neru Munshi
-
Publication number: 20100113405Abstract: The present invention relates to new methylindazole modulators of 5-HT3 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 4, 2009Publication date: May 6, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100105758Abstract: Uses for a selective adenosine A3 receptor antagonist, or RNAi directed against said receptor, to treat myocardial infarction and heart conditions including heart failure, are provided. Optionally, an adenosine A2a receptor agonist may also be used with the adenosine A3 receptor antagonist. Methods of treating heart failure are also provided.Type: ApplicationFiled: November 8, 2007Publication date: April 29, 2010Applicant: Centre de Recherche Public de la SanteInventors: Daniel R. Wagner, Yvan Devaux
-
Publication number: 20100098758Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed.Type: ApplicationFiled: December 23, 2009Publication date: April 22, 2010Applicant: GRUENENTHAL GmbHInventors: Johannes BARTHOLOMÄUS, Klaus-Dieter Langner
-
Patent number: 7700615Abstract: Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.Type: GrantFiled: February 1, 2006Date of Patent: April 20, 2010Assignee: Avolix Pharmaceuticals, Inc.Inventors: David L. Edwards, Michael E. Berens, Christian Beaudry
-
Patent number: 7696222Abstract: Compounds according to formula (I) wherein the radicals R1, R2 and R3 are as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from —C(Ra)(Rb)—, —C(Ra)(Rb)—C(Ra)(Rb)—, —C(Ra)?C(Ra)—, OC(Ra)(Rb)— or SC(Ra)(Rb)—. These compounds and their pharmaceutical acceptable salts are used in pharmaceutical compositions as prostaglandine D2 receptor antagonists useful in the treatment of CRTH2-mediated diseases such as respiratory, inflammatory or allergic conditions among others.Type: GrantFiled: August 7, 2006Date of Patent: April 13, 2010Assignee: Merck Frosst Canada LtdInventor: Zhaoyin Wang
-
Publication number: 20100087476Abstract: This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 8, 2009Publication date: April 8, 2010Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventors: Andrew John Duffield, Neil Andrew Williams
-
Publication number: 20100087475Abstract: This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.Type: ApplicationFiled: September 8, 2009Publication date: April 8, 2010Applicant: Biovali Laboratories International (Barbados) S.R.L.Inventors: Andrew John Duffield, Grant Johnston, Brendan Mark Green, John Christopher Townsley
-
Publication number: 20100087424Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials.Type: ApplicationFiled: April 17, 2008Publication date: April 8, 2010Inventors: Pamela Brown, Steven Dabbs
-
Publication number: 20100063086Abstract: This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventor: Philip Paul Nichols
-
Publication number: 20100055133Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonlus, dystoniia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: August 12, 2009Publication date: March 4, 2010Applicant: Biovail Laboratories International (Barbados) S.R.LInventors: Andrew John Duffield, Graham Jackson, Steven E. Frisbee
-
Publication number: 20100056502Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials.Type: ApplicationFiled: March 20, 2008Publication date: March 4, 2010Applicant: GLAXO GROUP LIMITEDInventors: Pamela Brown, Steven Dabbs, David Thomas Davies, Neil David Pearson
-
Publication number: 20100048544Abstract: Tricyclic nitrogen-containing compounds of Formula (I) or pharmaceutically acceptable salts and/or N-oxides thereof: compositions containing them, their use in the treatment of tuberculosis, and methods for the preparation of such compounds.Type: ApplicationFiled: April 10, 2008Publication date: February 25, 2010Inventors: Lluis Ballell-Pages, David Barros-Aguirre, Julia Castro-Pichel, Modesto Jesus Remuinan-Blanco, Jose Maria Fiandor-Roman
-
Publication number: 20100047359Abstract: The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) a compound of formula 1, in which A represents a group selected from (I), (II) or (III), R and R? each representing hydrogen or in combination form a group selected from a single bond, —CH2— and —O—, and in which X? represents a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, preferably fumaric acid, oxalic acid, diacetic acid or a sterically demanding amino acid and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid.Type: ApplicationFiled: November 6, 2007Publication date: February 25, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Michael Trunk, Claudius Weiler, Werner Pieroth
-
Publication number: 20100009985Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: May 7, 2009Publication date: January 14, 2010Applicant: ALLERGAN, INC.Inventors: Santosh C. SINHA, Smita S. BHAT, Ken CHOW, Richard L. BEARD, John E. DONELLO, Michael E. GARST
-
Publication number: 20090325868Abstract: Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.Type: ApplicationFiled: May 12, 2008Publication date: December 31, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Yang Liu, Pan Zheng, Xing Chang, Lizhong Wang, Runhua Liu, Yin Wang, Yan Liu, Tao Zuo
-
Publication number: 20090306122Abstract: Compound of the formula (I), in which X, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.Type: ApplicationFiled: February 13, 2006Publication date: December 10, 2009Inventors: Wolfgang Staehle, Timo Heinrich, Maria Kordowicz, Andree Blaukat, Lars Thore Burgdorf
-
Publication number: 20090285873Abstract: The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.Type: ApplicationFiled: June 15, 2009Publication date: November 19, 2009Applicant: Abbott Cardiovascular Systems Inc.Inventors: FLORENCIA LIM, Mikael O. Trollsas, Michael H. Ngo, Jie Hu, Syed F. A. Hossainy, David J. Sherman
-
Publication number: 20090286825Abstract: Compounds according to formula (I) wherein the radicals R1, R2 and R3 are as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from —C(Ra)(Rb)—, —C(Ra)(Rb)—C(Ra)(Rb)—, —C(Ra)?C(Ra)—, OC(Ra)(Rb)— or SC(Ra)(Rb)—. These compounds and their pharmaceutical acceptable salts are used in pharmaceutical compositions as prostaglandine D2 receptor antagonists useful in the treatment of CRTH2-mediated diseases such as respiratory, inflammatory or allergic conditions among others.Type: ApplicationFiled: August 7, 2006Publication date: November 19, 2009Inventor: Zhaoyin Wang
-
Publication number: 20090258895Abstract: The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the macrolide. The pharmaceutical formulation according to the invention is bioequivalent to the FDA approved product according to a bioavailability study conducted in humans.Type: ApplicationFiled: April 11, 2008Publication date: October 15, 2009Applicant: ROXANE LABORATORIES, INC.Inventors: Greg A. BRUBAKER, Thomas D. MAHON
-
Publication number: 20090192147Abstract: The invention relates to [a]-fused indole compounds of the Formula II, or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein. The invention also relates to compositions comprising the compounds of Formula II, and methods for making and using the compounds.Type: ApplicationFiled: January 30, 2009Publication date: July 30, 2009Applicant: WyethInventors: Semiramis Ayral-Kaloustian, Nan Zhang, Aranapakam Mudumbai Venkatesan, Tarek Suhayl Mansour, Thai Hiep Nguyen, James Thomas Anderson
-
Publication number: 20090163451Abstract: The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT1B or 5HT1D receptor agonist, (e.g., a triptan). These methods can be used, for example, to treat a human suffering from visceral pain secondary to an underlying disease of a visceral organ, such as pancreatitis. Visceral pain treatable by the methods of the invention may also be secondary to a disease of the liver, kidney, ovary, uterus, bladder, bowel, stomach, esophagus, duodenum, intestine, colon, spleen, pancreas, appendix, heart, or peritoneum.Type: ApplicationFiled: November 17, 2008Publication date: June 25, 2009Inventors: Frank Porreca, Louis P. Vera-Portocarrero
-
Publication number: 20090117040Abstract: The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.Type: ApplicationFiled: February 11, 2005Publication date: May 7, 2009Applicant: Max-Delbrug-Centrum Fur Molekulare MedizinInventors: Erich Wanker, Sabine Engemann, Susanne Rautenberg, Annett Boeddrich, Phoebe Markovic, Dagmar Ehrnhofer, Martin Herbst, Jacqueline Walther
-
Publication number: 20090117125Abstract: The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications.Type: ApplicationFiled: November 7, 2008Publication date: May 7, 2009Inventors: Tsann-Long Su, Ting-Chao Chou
-
Publication number: 20090105285Abstract: A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.Type: ApplicationFiled: May 9, 2007Publication date: April 23, 2009Applicant: NOVARTIS AGInventor: Heidi Lane
-
Publication number: 20090062222Abstract: The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies.Type: ApplicationFiled: September 29, 2006Publication date: March 5, 2009Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Michael Sherman, Stuart K Calderwood, Nava Zaarur
-
Publication number: 20090062269Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: February 2, 2007Publication date: March 5, 2009Inventors: Subharekha Raghavan, Darby Rye Schmidt, Steven L. Colletti, Abigail Lee Smenton
-
Publication number: 20090054423Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: April 7, 2006Publication date: February 26, 2009Inventors: Jason E. Imbriglio, Steven L. Colletti, James R. Tata, Rui Liang, Subharekha Raghavan, Darby R. Schmidt, Abigail L. Smenton, Sook Yee Chan
-
Publication number: 20090028785Abstract: Described herein are implantable coated medical devices, such as intravascular stents, for delivering therapeutic agents to the body tissue of a patient, and methods for making such medical devices. In particular, described herein are implantable coated medical devices comprising a substrate having a surface, and a coating disposed upon the surface that comprises a coating composition that includes a releasable metal oxide. The coating is free of polymer or a particular type of polymer that is not a part of any releasable metal oxide.Type: ApplicationFiled: July 18, 2008Publication date: January 29, 2009Applicant: Boston Scientific Scimed, Inc.Inventor: John T. Clarke
-
Publication number: 20090011020Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.Type: ApplicationFiled: March 6, 2006Publication date: January 8, 2009Applicant: ALFA WASSERMANN S.P.A.Inventors: Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo
-
Publication number: 20080319000Abstract: The invention provides 3,11b-cis-dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease in a patient, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait.Type: ApplicationFiled: July 13, 2006Publication date: December 25, 2008Applicant: CAMBRIDGE LABORATORIES (IRELAND) LIMITEDInventors: Robert Tridgett, Thierry Filloux
-
Patent number: 7462628Abstract: Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an ?1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.Type: GrantFiled: January 18, 2006Date of Patent: December 9, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuji Ishihara, Yuji Ishichi, Takayuki Doi, Hiroshi Nagabukuro, Naoyuki Kanzaki, Motoki Ikeuchi
-
Publication number: 20080280892Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials.Type: ApplicationFiled: October 17, 2006Publication date: November 13, 2008Inventors: Nathalie Cailleau, David Thomas Davies, Joel Michael Esken, Alan Joseph Hennessy, Senthil Kumar Kusalakumari Sukumar, Roger Edward Markwell, Timothy James Miles, Neil David Pearson
-
Publication number: 20080280886Abstract: Disclosed herein are urea-based 5-HT receptor modulators, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of 5-HT receptor-mediated disorders.Type: ApplicationFiled: May 8, 2008Publication date: November 13, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080269275Abstract: Compounds of Formula I wherein R1, D, R2, A and R3 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: May 29, 2006Publication date: October 30, 2008Applicant: ASTRAZENECA ABInventors: Dean Brown, William Blackwell, Frances M. McLaren, Volker Schnecke, Reed W. Smith, Gary Steelman, Xia Wang, Rebecca Urbanek, Steven Wesolowski
-
Publication number: 20080269276Abstract: The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.Type: ApplicationFiled: February 8, 2008Publication date: October 30, 2008Applicant: Dynogen Pharmaceuticals, Inc.Inventors: Steven B. Landau, Suhail Nurbhai
-
Publication number: 20080262023Abstract: The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 20, 2008Publication date: October 23, 2008Applicant: Abbott LaboratoriesInventors: Lei Shi, Marc J.C. Scanio, William H. Bunnelle
-
Publication number: 20080262024Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.Type: ApplicationFiled: May 13, 2008Publication date: October 23, 2008Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20080255180Abstract: The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 20, 2008Publication date: October 16, 2008Applicant: ABBOTT LABORATORIESInventor: William H. Bunnelle
-
Publication number: 20080255178Abstract: The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 20, 2008Publication date: October 16, 2008Applicant: ABBOTT LABORATORIESInventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Lei Shi
-
Publication number: 20080255179Abstract: The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 20, 2008Publication date: October 16, 2008Applicant: ABBOTT LABORATORIESInventors: Marc J.C. Scanio, Lei Shi, William H. Bunnelle, Michael R. Schrimpf
-
Publication number: 20080221090Abstract: The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: March 3, 2008Publication date: September 11, 2008Inventors: Kap-Sun Yeung, John F. Kadow
-
Publication number: 20080213363Abstract: Compositions, methods, and formulations for delivering 5-HT3 antagonists across the oral mucosa are described. In some variations, the described compositions comprise at least one 5-HT3 antagonist, which is at least partly in an ionized form, and a buffer system. The buffer system generally comprises at least two different buffering agents and is capable of changing the pH of saliva from an arbitrary initial pH to a predetermined final pH, and of sustaining the final pH for a period of time. The predetermined final pH favors substantially complete conversion of the ionized form to the un-ionized form. In other variations, the described compositions comprise a 5-HT3 antagonist, at least partly in an un-ionized form, and a buffer system. In these variations, the buffer system is capable of providing an adjusted salival pH such that the 5-HT3 antagonist remains in its un-ionized form. Dissolving tablets are also described.Type: ApplicationFiled: January 22, 2004Publication date: September 4, 2008Inventors: Nikhilesh N. Singh, Natasha N. Singh
-
Publication number: 20080167336Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.Type: ApplicationFiled: November 5, 2007Publication date: July 10, 2008Applicant: Abbott LaboratoriesInventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G.Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry